

IDERA PHARMACEUTICALS, INC.

Form DEF 14A

April 25, 2016

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

(RULE 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No.)

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to § 240.14a-12

IDERA PHARMACEUTICALS, INC.

(Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if Other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

- 1) Title of each class of securities to which transaction applies:
- 2) Aggregate number of securities to which transaction applies:
- 3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
- 4) Proposed maximum aggregate value of transaction:
- 5) Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

- 1) Amount Previously Paid:
 - 2) Form, Schedule or Registration Statement No.:
 - 3) Filing Party:
 - 4) Date Filed:
-

Table of Contents

IDERA PHARMACEUTICALS, INC.

167 Sidney Street

Cambridge, Massachusetts 02139

NOTICE OF 2016 ANNUAL MEETING OF STOCKHOLDERS

3

Date and Time: Monday, June 13, 2016 at 3:00 p.m., local time

Place: Idera Pharmaceuticals, Inc.
505 Eagleview Boulevard
Suite 212
Exton, Pennsylvania 19341

Items of Business: At our 2016 annual meeting of stockholders we will ask our stockholders to:

Elect three Class III directors to our board of directors for terms to expire at the 2019 annual meeting of stockholders;

Approve, by non-binding vote, executive compensation;

Ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016; and

Transact any other business as may properly come before the 2016 annual meeting or any postponement or adjournment of the 2016 annual meeting.

The board of directors has no knowledge of any other business to be transacted at the 2016 annual meeting.

Record Date: You may vote at the 2016 annual meeting if you were a stockholder of record at the close of business on April 20, 2016.

Proxy Voting: It is important that your shares be represented and voted at the 2016 annual meeting. Whether or not you plan to attend the 2016 annual meeting, please mark, sign, date and promptly mail your proxy card in the enclosed postage-paid envelope or follow the instructions on the proxy card to vote by telephone or over the internet. You may revoke your proxy at any time before its exercise at the 2016 annual meeting.

By order of the board of directors,

/s/ Mark J. Casey
Mark J. Casey
General Counsel and Secretary
Cambridge, Massachusetts
April 25, 2016

Table of Contents

TABLE OF CONTENTS

<u>PROXY STATEMENT</u>	1
<u>INFORMATION ABOUT THE 2016 ANNUAL MEETING</u>	2
<u>Who may vote?</u>	2
<u>How do I vote my shares if I am a stockholder of record?</u>	2
<u>How do I vote my shares if I hold them in “street name?”</u>	2
<u>How may I change or revoke my vote?</u>	3
<u>What constitutes a quorum?</u>	3
<u>What vote is required to approve each matter and how will votes be counted?</u>	4
<u>How does the board of directors recommend that I vote?</u>	4
<u>Will any other business be conducted at the 2016 annual meeting of stockholders?</u>	4
<u>Who is making and paying for the solicitation of proxies and how is it made?</u>	4
<u>How and when may I submit a proposal for the 2017 annual meeting of stockholders?</u>	5
<u>Are annual meeting materials householded?</u>	5
<u>PROPOSAL ONE ELECTION OF DIRECTORS</u>	6
<u>General Information</u>	6
<u>Information about our Directors</u>	6
<u>Director Compensation</u>	9
<u>CORPORATE GOVERNANCE INFORMATION</u>	12
<u>Board of Directors</u>	12
<u>Board Leadership Structure</u>	12
<u>Board’s Role in Risk Oversight</u>	12
<u>Board Committees</u>	12
<u>Director Independence</u>	14
<u>Director Nomination Process</u>	15
<u>Stockholder Nominees</u>	15
<u>Communicating with our Board of Directors</u>	16
<u>Compensation Committee Interlocks and Insider Participation</u>	16
<u>Executive Officers of Idera</u>	17
<u>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</u>	18
<u>EXECUTIVE COMPENSATION</u>	22
<u>Compensation Discussion and Analysis</u>	22
<u>Agreements with our Named Executive Officers</u>	32
<u>Formal Clawback Policy</u>	35
<u>Compensation Committee Report</u>	36
<u>Summary Compensation Table</u>	36
<u>Grants of Plan-Based Awards</u>	37
<u>Outstanding Equity Awards at Fiscal Year-End</u>	38
<u>Option Exercises and Stock Vested</u>	39
<u>Potential Payments Upon Termination or Change in Control</u>	39
<u>EQUITY COMPENSATION PLAN INFORMATION</u>	42

<u>PROPOSAL TWO APPROVAL, BY NON-BINDING VOTE, OF EXECUTIVE COMPENSATION</u>	43
<u>PROPOSAL THREE RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</u>	45
<u>ACCOUNTING MATTERS</u>	46
<u>Report of the Audit Committee</u>	46
<u>Independent Registered Public Accounting Firm Fees</u>	46
<u>Pre-Approval Policies and Procedures</u>	47
<u>TRANSACTIONS WITH RELATED PERSONS</u>	48
<u>Public Offering</u>	